Respuesta inmunológica a la vacunación y riesgo de COVID-19 en adultos con neoplasias hematológicas

Jorge Alberto Cortés, Laura Cristina Nocua-Báez, Cándida Díaz-Brochero, Sonia Isabel Cuervo Maldonado

Producción: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

Resumen

Patients with hematological malignancies have a higher risk of hospital admission, critical care and death when they suffer from COVID-19. In this group of patients, vaccination and boosters have been proposed to mitigate the risk of complications. However, it is possible to observe a diminished rate of humoral and cellular response. In this review, evidence is shown about the response to COVID-19 vaccination, considering some specific pathologies and treatments that can affect such response in a significant account. Patients with malig-nant neoplasm must be considered at risk of COVID-19 complications, even after a complete vaccine schedule and boosters. Surveillance must be maintained after vaccination over these patients and other strategies must be considered (drugs, monoclonal antibodies) for prevention and management of COVID-19.

Título traducido de la contribuciónImmunological response to vaccination and risk of COVID-19 in adults with hematological malignancies
Idioma originalEspañol
Páginas (desde-hasta)228-235
Número de páginas8
PublicaciónRevista Chilena de Infectologia
Volumen40
N.º3
DOI
EstadoPublicada - jun. 2023
Publicado de forma externa

Palabras clave

  • COVID-19
  • hematologic neoplasms
  • immunosuppression therapy
  • vaccination

Huella

Profundice en los temas de investigación de 'Respuesta inmunológica a la vacunación y riesgo de COVID-19 en adultos con neoplasias hematológicas'. En conjunto forman una huella única.

Citar esto